# Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

> **NCT05554406** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 335 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
- Acute Myeloid Leukemia Post Cytotoxic Therapy
- Acute Myeloid Leukemia, Myelodysplasia-Related

## Interventions

- **DRUG:** Azacitidine
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin Hydrochloride
- **PROCEDURE:** Echocardiography Test
- **DRUG:** Liposome-encapsulated Daunorubicin-Cytarabine
- **PROCEDURE:** Multigated Acquisition Scan
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05554406
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 335 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05554406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05554406, "Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05554406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*